Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1986 Nov;83(21):8019-23.
doi: 10.1073/pnas.83.21.8019.

Primary structure of blood coagulation factor XIIIa (fibrinoligase, transglutaminase) from human placenta

N Takahashi, Y Takahashi, F W Putnam

Primary structure of blood coagulation factor XIIIa (fibrinoligase, transglutaminase) from human placenta

N Takahashi et al. Proc Natl Acad Sci U S A. 1986 Nov.

Abstract

We have determined the primary structure of human placental factor XIIIa, an enzyme [fibrinoligase, transglutaminase, fibrin-stabilizing factor, EC 2.3.2.13 (protein-glutamine:amine gamma-glutamyltransferase)] that forms intermolecular isopeptide bonds between fibrin molecules as the last step in blood coagulation. Placental factor XIIIa is an unglycosylated polypeptide chain of 730 amino acid residues (Mr = 83,005) that appears to be identical to the a subunit of the plasma zymogen factor XIII. Ca2+-dependent activation of factor XIIIa by thrombin removes a blocked amino-terminal peptide and unmasks a reactive thiol group at Cys-314. A second specific cleavage after Lys-513 by thrombin inactivates factor XIIIa and produces an amino-terminal 56-kDa fragment and a 24-kDa fragment. The amino acid sequence of factor XIIIa is unique and does not exhibit internal homology, but its active center is similar to that of the thiol proteases. The probable Ca2+-binding site of factor XIIIa has been identified by homology to the high-affinity sites in calmodulins. Knowledge of the primary structure of factor XIIIa will aid elucidation of the mechanism of its enzymatic action and that of the many tissue transglutaminases of which it is the prototype. This will also facilitate production of factor XIIIa by recombinant DNA technology for use in treatment of congenital factor XIII deficiencies and in the postoperative healing of wounds.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. J Biol Chem. 1966 Jul 10;241(13):3238-40 - PubMed
    1. Proc Natl Acad Sci U S A. 1986 Nov;83(21):8024-8 - PubMed
    1. Ann N Y Acad Sci. 1972 Dec 8;202:256-72 - PubMed
    1. J Biol Chem. 1973 Feb 25;248(4):1395-407 - PubMed
    1. Biochemistry. 1974 Feb 12;13(4):750-6 - PubMed

Publication types

LinkOut - more resources